A double blind randomized clinical trial of buprenorphine augmentation for treatment of psychotic symptoms in opioid addicted bipolar patients

Navid Khalili, MD; Abdolreza Sabahi, MD; Mostafa Vahedian, PhD; Mehdi Alimardanzadeh, MD

doi:10.5055/jom.2019.0525

Authors

Navid Khalili, MD
Abdolreza Sabahi, MD
Mostafa Vahedian, PhD
Mehdi Alimardanzadeh, MD

DOI:

https://doi.org/10.5055/jom.2019.0525

Keywords:

buprenorphine, psychosis, bipolar disorder, clinical trial

Abstract

Objective: To assess the efficacy of buprenorphine augmentation in treatment of psychotic symptoms in bipolar disorder type I.

Design: Bipolar type I patients with manic or depressive episodes and psychotic feature and with opioid dependency comorbidity were randomly included and allocated. Both groups of buprenorphine (4 or 6 mg/d) and placebo were also treated with enough dosages of sodium valproate and risperidone. Psychosis as primary outcome and depressive and manic symptoms as secondary outcome were assessed at baseline and after 1 and 2 weeks. Data were analyzed through t test and repeated measure ANOVA.

Results: Twenty-four patients remained in each group. Both groups displayed significant reduction in psychotic, depressive, and manic symptoms during the 2 weeks of study, although there was not any significant difference between them.

Conclusions: Buprenorphine did not add any efficacy to usual treatment of psychotic episodes of bipolar, although did not aggravate psychiatric symptoms.

Author Biographies

Navid Khalili, MD

Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

Abdolreza Sabahi, MD

Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

Mostafa Vahedian, PhD

Neuroscience Research Center, Qom University of Medical Sciences, Qom, Iran

Mehdi Alimardanzadeh, MD

Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

References

Maremmani I, Pacini M, Pani PP: Effectiveness of buprenorphine in double diagnosed patients. Buprenorphine as psychothropic drug. Heroin Addict Relat Clin Probl. 2006; 8 (1): 31-48.

Maremmani AG, Rovai L, Rugani F, et al.: Substance abuse and psychosis. The strange case of opioids. Eur Rev Med Pharmacol Sci. 2014; 18 (3): 287-302.

Schmauss C, Yassouridis A, Emrich HM: Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987; 144 (10): 1340-1342.

Weibel S, Mallaret M, Bennouna-Greene M, et al.: A case of acute psychosis after buprenorphine withdrawal: Abrupt versus progressive discontinuation could make a difference. J Clin Psychiatry. 2012; 73 (6): e756.

Karila L, Berlin I, Benyamina A, et al.: Psychotic symptoms following buprenorphine withdrawal. Am J Psychiatry. 2008; 165 (3): 400-401.

Cobo J, Ramos MM, Pelaez T, et al.: Psychosis related to methadone withdrawal. Acta Neuropsychiatr. 2006; 18 (1): 50-51.

MacEvilly M, O’Carroll C: Hallucinations after epidural buprenorphine. BMJ. 1989; 298 (6678): 928-929.

Khalili N, Gudarzi SS: Opioid withdrawal-induced hypomania: A case series. J Opioid Manag. 2012; 8 (1): 67-72.